Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) ranks 5th on this list.

While Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) faces high cash burn, hedge funds are piling into the stock due to its successful precision obesity pivot, which separates it from the broad-market GLP-1 (Ozempic/Wegovy) hype. In recent months, the firm has registered a series of landmark regulatory wins for their lead drug, IMCIVREE. In mid-March, the FDA granted full approval for IMCIVREE to treat acquired hypothalamic obesity, a high-unmet-need market. In late March, an EU body issued a positive opinion for the same indication. Funds view this as a transformative label expansion. Unlike generic obesity, hypothalamic obesity is rare and often follows brain tumors or surgery. This gives Rhythm a 100% market monopoly in this niche, providing pricing power that broad-market drugs cannot match.

There is also renewed focus on the rapidly scaling top-line performance of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). For the full year 2025, the firm reported a 50% year-over-year revenue increase, reaching roughly $194.8 million. Investors are positioning themselves in the stock ahead of the clinical shift from daily injections to oral pills. In early 2026, Rhythm initiated its Phase 3 trials for bivamelagon, a once-daily oral MC4R agonist. Smart money managers realize that an oral version would drastically increase patient adherence and market penetration.

READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.